PharmAla Issues Audited Financial Statements, Completes Continuance to Ontario, and Closes Private Placement
20. Dezember 2024 16:55 ET
|
PharmAla Biotech
PharmAla files audited financials for year ended August 31, 2024, completes continuance and oversubscribed private placement
PharmAla Announces Private Placement
13. Dezember 2024 09:25 ET
|
PharmAla Biotech
PharmAla announces private placement financing
MAPS Launches ‘Music is the Bridge’ Campaign Featuring Lil Yachty, Melissa Etheridge, Reggie Watts and More
09. Dezember 2024 09:00 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS’ “Music is the Bridge” blends artist playlists & free psychedelic education, inspiring exploration and connection. Visit MAPS.org/music-is-the-bridge
Psychedelic Science 2025 Conference Announces Workshops, Holiday Sale, and Scholarship Deadline
05. Dezember 2024 15:44 ET
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
World’s leading psychedelic conference kicks off with workshops from leaders in science, medicine, therapy, policy, Indigenous medicine, and societyUpcoming deadline: speaker submissions, initial...
PharmAla Reaches Agreement in Principle to Supply MDMA to Clinical Trial in Exchange for Full Data License
14. November 2024 09:20 ET
|
PharmAla Biotech
PharmAla reaches agreement in principle to trade with a clinical trial to trade its LaNeo MDMA for a data license to the trial outcomes.
PharmAla to supply LaNeo MDMA for Clinical Trial at Yale
07. November 2024 09:20 ET
|
PharmAla Biotech
PharmAla to supply Yale University with MDMA for clinical trial
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
21. Oktober 2024 09:25 ET
|
PharmAla Biotech
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.
KCSA Strategic Communications Wins Coveted PRNEWS Platinum Award for Maps’ Psychedelic Science 2023 Conference
10. Oktober 2024 16:06 ET
|
KCSA Strategic Communications
KCSA Strategic Communications wins the PRNEWS Platinum Award for “Best Conference Marketing/PR Campaign” for Psychedelic Science 2023 (PS2023) Conference
PharmAla to supply the University of Texas, San Antonio, with novel dosage form of LaNeo™ MDMA
08. Oktober 2024 08:55 ET
|
PharmAla Biotech
PharmAla signs contract to develop novel dosage form of LaNeo MDMA, to be used in clinical trial at University of Texas San Antonio
PharmAla to supply Harvard Medical School’s Maclean Hospital with LaNeo MDMA
02. Oktober 2024 09:20 ET
|
PharmAla Biotech
PharmAla Biotech signs contract to supply Harvard neuropsychiatry hospital with MDMA; Appears at CPHI Conference in Milan